advertisement
11.16 Vehicles, delivery systems, pharmacokinetics, formulation (5)
Showing records 1 to 5
Search within classification 11.16 Vehicles, delivery systems, pharmacokinetics, formulation15219 Trefoil factor family 1, MUC5AC and human leucocyte antigen-DR expression by conjunctival cells in patients with glaucoma treated with chronic drugs: could these markers predict the success of glaucoma surgery?
Souchier M; Buron N; Lafontaine PO; Bron AM; Baudouin C; Creuzot-Garcher C
British Journal of Ophthalmology 2006; 90: 1366-1369
15144 Human scleral hydraulic conductivity: age-related changes, topographical variation, and potential scleral outflow facility
Jackson TL; Hussain A; Hodgetts A; Morley AM; Hillenkamp J; Sullivan PM; Marshall J
Investigative Ophthalmology and Visual Science 2006; 47: 4942-4946
15122 Improved systemic safety and risk-benefit ratio of topical 0.1% timolol hydrogel compared with 0.5% timolol aqueous solution in the treatment of glaucoma
Uusitalo H; Kahonen M; Ropo A; Maenpaa J; Bjarnhall G; Hedenstrom H; Turjanmaa V
Graefe's Archive for Clinical and Experimental Ophthalmology 2006; 244: 1491-1496
14556 Hypersensitivity reactions to ophthalmic products
Ventura MT; Viola M; Gaeta F; Di Leo E; Buquicchio R; Romano A
Current Pharmaceutical Design 2006; 12: 3401-3410
14936 Antiglaucoma drugs - content of preservatives and the patient's compliance
Vyborny P; Sejckova L
Česka a Slovenska Oftalmologie 2006; 62: 270-272, 274
